Vanguard Health Care ETF news

VHT is recommended as the better choice for most investors due to significantly lower expense ratio (0.09% vs 0.37%), broader diversification with 411 holdings, higher dividend yield (1.4%), and identical long-term performance to its competitor at a lower cost.

Recommended as a safe bet during inflation concerns with solid 5-year returns of 5.4%, Zacks Rank #2 (Buy), and lowest expense ratio of 0.33%

VHT receives a Strong Buy rating (Zacks ETF Rank 1), has one of the lowest expense ratios at 0.09%, substantial assets of $20.15 billion, strong year-to-date performance of 24.95%, and provides effective diversification with 420 holdings across the healthcare sector.

Highlighted for its broad diversification across 411 holdings, significantly lower expense ratio (0.09%), higher dividend yield (1.4%), lower volatility (17.7% max drawdown), and suitability for long-term conservative investors seeking stability.

Offers significantly lower expense ratio (0.09%), higher dividend yield (1.5%), broad diversification with 411 holdings, lower volatility (max drawdown -17.7%), and is recommended for long-term investors seeking stability and income.

Recommended as a defensive, low-risk investment with solid 3-year (6.7%) and 5-year (5.1%) annualized returns, low expense ratio of 0.33%, and Zacks Mutual Fund Rank #2 rating.

Praised for low expense ratio (0.09%), broad diversification (411 holdings), higher dividend yield (1.5%), and better year-to-date performance (12% vs 8%). Positioned as the more affordable and stable choice.

VHT is recommended as the better choice for long-term investors, with superior 1-year returns (30.1%), broader diversification across 423 holdings including small and mid-cap stocks, and better performance across most time frames (3-year, 10-year). The article concludes VHT is the preferred option despite slightly higher expense ratio.

Praised for broad diversification (423 holdings), extremely low expense ratio (0.09%), steady performance (27.85% 1-year return), and lower volatility (17.71% max drawdown). Recommended for conservative investors seeking stable, low-cost healthcare exposure.

VHT is presented as the superior choice with lower expense ratio (0.09%), higher dividend yield (1.6%), better 5-year returns ($1,278 vs $1,004), lower maximum drawdown (17.7% vs 39.9%), and broader diversification across 411 holdings. Recommended for traditional investors seeking steady performance.

VHT is recommended as the stronger long-term choice due to its very low expense ratio (0.09%), broad diversification across 400+ healthcare companies, dividend yield (1.6%), lower volatility (max drawdown of 17.7%), and larger AUM ($20.4B), making it ideal for stability-focused investors.

Praised for low expense ratio (0.09%) and broad diversification with 411 holdings across the healthcare ecosystem, but criticized for underperformance relative to IHE over recent years (5.4% vs 11.8% over 5 years). Recommended for cost-conscious, diversification-focused investors.

VHT is praised for its rock-bottom expense ratio of 0.09%, higher dividend yield of 1.60%, broad diversification across 411 healthcare stocks, and strong 1-year performance of 25.20%. However, it underperforms PJP over longer timeframes.

Up 5.6% for the month ending July 10, near 52-week highs, supported by strong second-quarter earnings guidance and tailwinds from biotech and obesity drugs (Goldman Sachs raised 2030 obesity drug sales forecast by 15%)

Praised for broad diversification (429 holdings), significantly lower expense ratio (0.09%), larger AUM ($20.4B), and lower volatility (beta 0.59). Recommended as the more affordable and prudent choice for most investors.

Despite Wall Street's bullish outlook, the author is skeptical due to historical underperformance versus S&P 500 (148% vs 329% over past decade), expensive valuation at 27x earnings, slow earnings growth forecast (3% in 2026), and significant pharmaceutical patent cliff headwinds affecting one-third of holdings.

VHT is presented favorably with significantly lower expense ratio (0.09%), higher dividend yield (1.69%), broader diversification (411 holdings), superior 5-year returns (25% total return vs 6% for XBI), and lower volatility (max drawdown -17% vs -55%). Recommended for most investors seeking healthcare exposure.

Outperformed S&P 500 with 27% gain, Q4 earnings growth forecasted at 13%, and positive sector fundamentals in biopharma and managed care with low regulatory risk in near term.

Substantial fund ($20.8B net assets) with 12.93% LLY weighting, 22% YTD gains, and low 9 bps fees offer broad healthcare sector exposure with LLY as top holding.

VHT is presented as a superior alternative with $20.24 billion in assets and a much lower 0.09% expense ratio, offering traditional market cap weighted exposure at lower cost.

Presented as an alternative healthcare ETF option with $20.07 billion in assets and a 0.09% expense ratio; no comparative advantage or disadvantage stated.

Presented as an alternative option with significantly lower expense ratio (0.09% vs IYH's 0.37%) and substantially larger assets ($20.10 billion), making it a more cost-efficient competitor.

Presented as an alternative with significantly lower expense ratio (0.09% vs FXH's 0.61%) and substantially larger assets ($19.75 billion), making it a more cost-efficient option for healthcare exposure.

Recommended as a resilient, non-cyclical investment with 416 diversified holdings. Healthcare demand remains stable during recessions, and the fund has delivered 757% total return since inception with low 0.09% expense ratio.

Presented as a superior alternative with significantly lower expense ratio (0.09% vs 0.5%) and substantially larger asset base ($19.41 billion), offering better value for healthcare sector exposure.

Presented as a superior alternative with significantly lower expense ratio (0.09% vs RSPH's 0.40%) and substantially larger assets ($19.27 billion), making it more attractive for cost-conscious investors.

Healthcare sector at lowest weighting in 30 years (8.3%) while AI commands 40% of market cap; VHT down 5.5% year-to-date despite institutional attention, showing severe sector underperformance